Lung cancer is one of the major cancer types and poses challenges in its treatment, including lack of specificity and harm to healthy cells.Nanoparticle-based drug delivery systems (NDDSs) show promise in overcoming these challenges.While conventional NDDSs have drawbacks, such as immune response and capture by the reticuloendothelial system (RES), extracellular vesicles (EVs) present a potential solution.EVs, starburst halloween mix which are naturally released from cells, can evade the RES without surface modification and with minimal toxicity to healthy cells.
This makes them a promising candidate for developing a lung-cancer-targeting drug delivery system.EVs isolated from vascular endothelial cells, such as human umbilical endothelial-cell-derived EVs (HUVEC-EVs), have shown anti-angiogenic activity in a lung cancer mouse model; therefore, in this study, HUVEC-EVs were chosen as a copyright for drug delivery.To achieve lung-cancer-specific targeting, HUVEC-EVs were engineered to be decorated with GE11 peptides (GE11-HUVEC-EVs) via a postinsertional technique to target the epidermal growth factor receptor (EGFR) that is overexpressed on the surface of lung cancer cells.The GE11-HUVEC-EVs were loaded with vinorelbine (GE11-HUVEC-EVs-Vin), and then characterized and evaluated in in vitro and in vivo lung cancer models.
Further, we s1229rs examined the binding affinity of ABCB1, encoding P-glycoprotein, which plays a crucial role in chemoresistance via the efflux of the drug.Our results indicate that GE11-HUVEC-EVs-Vin effectively showed tumoricidal effects against cell and mouse models of lung cancer.